Program Description:
The pandemic outbreak of novel H1N1 influenza in 2009 led the Centers for Disease Control to focus its efforts on isolating the viral strains that could lead to accelerated development of a vaccine. Selected high-risk populations have been identified to receive priority administration of the vaccine when it becomes available in the United States. This educational program explores tactics to help Nurse Practitioners prevent the spread of H1N1 influenza and to treat and manage those patients who do contract this potentially deadly disease.
Activity Objectives:
At the conclusion of this Continuing Education (CE) activity, participants should be able to:
Describe the epidemiology, signs, and symptoms of H1N1 influenza and its potential complications Identify populations at high risk for H1N1 influenza List the Advisory Committee on Immunization Practices’ (ACIP) recommendations for preventing H1N1 influenza Explain the contraindications and adverse effects of H1N1 influenza vaccine and assess patients’ ability to receive it
|
Credits
|
Type
|
Accreditation Statement
|
Designation Statement
|
|
1.00
|
CE for Nurses
|
CNE Provider Unit, Boston University School of Medicine is accredited as a provider of CNE by the American Nurses Credentialing
|
Center’s Commission on Accreditation. Contact Hours: 1 Course Code: E.H1N1HAY09.
|
Faculty:
Gregory A. Poland, MD
Director, Vaccine Research Group
Mary Lowell Leary Professor of Medicine
Mayo Clinic College of Medicine
Mayo Clinic and Foundation,
Rochester, Minnesota
Thad R. Wilson, APRN, BC, PhD
Associate Dean for Clinical Programs
UMKC School of Nursing,
Kansas City, Missouri
Course Director/Designated Nurse Planner
Carole Moloney, MSN, CPNP
Pediatric Infectious Disease Department
Boston Medical Center, Boston, Massachusetts
Disclosures:
Faculty Disclosure Statement (includes Course Director):
Gregory A. Poland, MD, is a consultant for Avianax, Emergent BioSolutions, GlaxoSmithKline, Liquidia Technologies, MedImmune LLC, Merck and Co., Inc., Novartis Vaccines, Novavax, and Theraclone Sciences. He also receives grant/research support from Merck and Co., Inc., Novavax, and Wyeth. He serves as Chair for a Novel vaccine DMSB for Merck and Co., Inc.
Thad R. Wilson, APRN, BC, PhD, is on the speakers’ bureaus for Sanofi Pasteur, Inc. and Merck and Co., Inc. He serves on the advisory board for GlaxoSmithKline.
Carole Moloney, MSN, CPNP, serves on the speakers’ bureau for Sanofi Pasteur, Inc.
Ilana Hardesty and Claire Murphy, NP-C, Boston University School of Medicine, have nothing to disclose.
Susan Basilico, Liz Selkowe, and Debbie Walsh, Haymarket Medical Education, have nothing to disclose.
This program is provided by Boston University School of Medicine.
This program us supported by an educational grant from Merck & Co., Inc.
BOSTON UNIVERSITY SCHOOL OF MEDICINE DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR THE PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH-CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
Non-Endorsement of Products
Continuing Nursing Education Provider Unit, Boston University School of Medicine’s provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.
Commercial Supporter:
Merck and Co., Inc.
Instructions:
To obtain credit, you must have 70 percent or more of the answers correct. This CE is offered at no cost to participants. Please proceed with the course until you have successfully completed this program and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com, which you can then access at any time.
SYSTEM REQUIREMENTS:
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.